The CRELD1 (Cysteine-Rich with EGF-Like Domains 1) antibody is a tool used to detect and study the CRELD1 protein, a conserved cell surface or secreted glycoprotein involved in cell adhesion, signaling, and developmental processes. First identified for its role in cardiac development, CRELD1 is critical for atrioventricular septal formation, and mutations in its gene are linked to congenital heart defects, particularly atrioventricular septal defects (AVSDs). The protein contains epidermal growth factor (EGF)-like and cysteine-rich domains, suggesting interactions with extracellular matrix components or signaling receptors.
CRELD1 antibodies are widely employed in research to investigate its expression patterns, subcellular localization, and functional mechanisms. They are used in techniques like Western blotting, immunohistochemistry, and immunofluorescence, often in models ranging from mammalian cells to zebrafish. Studies have implicated CRELD1 in broader contexts, including endoplasmic reticulum stress response, Wnt signaling modulation, and tissue repair.
In disease research, CRELD1 antibodies help explore its dysregulation in cardiac malformations, cancer progression, and immune disorders. Recent evidence also points to its role in epithelial-mesenchymal transition (EMT) and fibrosis. Validated antibodies typically target specific epitopes, such as the N-terminal region, and are essential for distinguishing CRELD1 isoforms or post-translational modifications. As CRELD1's pleiotropic functions gain attention, its antibodies remain vital for unraveling its contributions to development and disease.